Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

HOTH

Hoth Therapeutics (HOTH)

Hoth Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:HOTH
FechaHoraFuenteTítuloSímboloCompañía
14/05/202415:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOTHHoth Therapeutics Inc
01/05/202407:00PR Newswire (US)Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024NASDAQ:HOTHHoth Therapeutics Inc
27/03/202413:00PR Newswire (US)Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross ProceedsNASDAQ:HOTHHoth Therapeutics Inc
27/03/202407:27PR Newswire (US)Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity TreatmentNASDAQ:HOTHHoth Therapeutics Inc
19/03/202407:21PR Newswire (US)Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZNASDAQ:HOTHHoth Therapeutics Inc
29/02/202407:38PR Newswire (US)Hoth Therapeutics Retains Venable LLP to Expand Its Patent PortfolioNASDAQ:HOTHHoth Therapeutics Inc
26/02/202407:11PR Newswire (US)Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting TherapeuticNASDAQ:HOTHHoth Therapeutics Inc
13/02/202410:45PR Newswire (US)Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024NASDAQ:HOTHHoth Therapeutics Inc
18/01/202407:20PR Newswire (US)Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill PatientsNASDAQ:HOTHHoth Therapeutics Inc
09/01/202414:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOTHHoth Therapeutics Inc
08/01/202416:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOTHHoth Therapeutics Inc
27/12/202307:21PR Newswire (US)Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of MiamiNASDAQ:HOTHHoth Therapeutics Inc
05/12/202307:33PR Newswire (US)Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling StudiesNASDAQ:HOTHHoth Therapeutics Inc
14/11/202307:37PR Newswire (US)Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KITNASDAQ:HOTHHoth Therapeutics Inc
10/11/202307:00PR Newswire (US)Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023NASDAQ:HOTHHoth Therapeutics Inc
05/10/202309:03PR Newswire (US)Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug DiscoveryNASDAQ:HOTHHoth Therapeutics Inc
02/10/202307:33PR Newswire (US)FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer PatientsNASDAQ:HOTHHoth Therapeutics Inc
15/09/202313:38PR Newswire (US)Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesNASDAQ:HOTHHoth Therapeutics Inc
14/09/202316:24Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HOTHHoth Therapeutics Inc
13/09/202312:43PR Newswire (US)Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesNASDAQ:HOTHHoth Therapeutics Inc
13/09/202307:16PR Newswire (US)Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid LeukemiaNASDAQ:HOTHHoth Therapeutics Inc
11/09/202309:04PR Newswire (US)Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer PatientsNASDAQ:HOTHHoth Therapeutics Inc
06/09/202307:12PR Newswire (US)Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexaNASDAQ:HOTHHoth Therapeutics Inc
21/08/202316:00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HOTHHoth Therapeutics Inc
09/08/202307:13PR Newswire (US)Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's DiseaseNASDAQ:HOTHHoth Therapeutics Inc
25/07/202307:12PR Newswire (US)Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical TrialNASDAQ:HOTHHoth Therapeutics Inc
19/07/202307:02PR Newswire (US)Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer TherapeuticNASDAQ:HOTHHoth Therapeutics Inc
27/06/202315:22Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:HOTHHoth Therapeutics Inc
27/06/202315:21Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:HOTHHoth Therapeutics Inc
14/06/202307:12PR Newswire (US)Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical SiteNASDAQ:HOTHHoth Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:HOTH